Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 13 | 2023 | 3163 | 1.650 |
Why?
|
Kidney Neoplasms | 13 | 2023 | 4251 | 1.440 |
Why?
|
Receptors, Androgen | 1 | 2023 | 1077 | 0.570 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 11733 | 0.500 |
Why?
|
Lung Neoplasms | 4 | 2021 | 13385 | 0.420 |
Why?
|
Angiogenesis Inhibitors | 2 | 2019 | 2047 | 0.400 |
Why?
|
Radiosurgery | 1 | 2021 | 1339 | 0.390 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2016 | 424 | 0.370 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5662 | 0.340 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2015 | 2509 | 0.330 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4909 | 0.320 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3634 | 0.300 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1052 | 0.300 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 5321 | 0.280 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 4739 | 0.280 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2024 | 782 | 0.280 |
Why?
|
Immunotherapy | 2 | 2019 | 4642 | 0.270 |
Why?
|
Piperazines | 1 | 2016 | 2522 | 0.250 |
Why?
|
Pyrazoles | 1 | 2015 | 2010 | 0.240 |
Why?
|
Neoplasms | 9 | 2022 | 22140 | 0.240 |
Why?
|
Androgen Antagonists | 2 | 2023 | 1408 | 0.220 |
Why?
|
Pyridines | 1 | 2015 | 2872 | 0.220 |
Why?
|
Caregivers | 2 | 2012 | 2244 | 0.210 |
Why?
|
Androgen Receptor Antagonists | 1 | 2023 | 125 | 0.210 |
Why?
|
Prostatic Neoplasms | 5 | 2022 | 11101 | 0.200 |
Why?
|
Terminal Care | 1 | 2012 | 1760 | 0.180 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2023 | 2223 | 0.170 |
Why?
|
Camptothecin | 1 | 2023 | 591 | 0.170 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 258 | 0.170 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 316 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 210 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2016 | 9278 | 0.150 |
Why?
|
Orotate Phosphoribosyltransferase | 1 | 2017 | 5 | 0.150 |
Why?
|
Orotidine-5'-Phosphate Decarboxylase | 1 | 2017 | 8 | 0.150 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 2813 | 0.140 |
Why?
|
Autopsy | 1 | 2021 | 1010 | 0.140 |
Why?
|
Palliative Care | 1 | 2012 | 3599 | 0.140 |
Why?
|
Retreatment | 1 | 2018 | 598 | 0.140 |
Why?
|
Androgens | 1 | 2023 | 1283 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 963 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 858 | 0.120 |
Why?
|
Culture Media | 1 | 2017 | 894 | 0.120 |
Why?
|
Drug Synergism | 1 | 2019 | 1756 | 0.120 |
Why?
|
Humans | 34 | 2024 | 761208 | 0.120 |
Why?
|
Immunomodulation | 1 | 2018 | 548 | 0.120 |
Why?
|
Acrylamides | 1 | 2016 | 259 | 0.110 |
Why?
|
Multienzyme Complexes | 1 | 2017 | 665 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1605 | 0.110 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2016 | 628 | 0.110 |
Why?
|
Aged, 80 and over | 9 | 2023 | 58952 | 0.110 |
Why?
|
Neoplastic Stem Cells | 1 | 2021 | 1348 | 0.100 |
Why?
|
Biopsy, Needle | 1 | 2018 | 1624 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2182 | 0.100 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 4107 | 0.100 |
Why?
|
Mutation | 5 | 2023 | 30002 | 0.100 |
Why?
|
Male | 19 | 2023 | 360693 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1422 | 0.100 |
Why?
|
Tissue Distribution | 1 | 2016 | 2263 | 0.100 |
Why?
|
Drug Interactions | 1 | 2016 | 1417 | 0.090 |
Why?
|
Neoadjuvant Therapy | 2 | 2021 | 2827 | 0.090 |
Why?
|
Uric Acid | 1 | 2017 | 807 | 0.090 |
Why?
|
Marital Status | 1 | 2012 | 425 | 0.090 |
Why?
|
Aniline Compounds | 1 | 2016 | 1073 | 0.090 |
Why?
|
Aged | 13 | 2023 | 169288 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3512 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11119 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1869 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1923 | 0.080 |
Why?
|
Neovascularization, Pathologic | 1 | 2019 | 2636 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2022 | 8530 | 0.080 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3873 | 0.080 |
Why?
|
Middle Aged | 13 | 2023 | 220853 | 0.070 |
Why?
|
Bereavement | 1 | 2011 | 309 | 0.070 |
Why?
|
Sex Distribution | 1 | 2012 | 2277 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9187 | 0.070 |
Why?
|
Age Distribution | 1 | 2012 | 2871 | 0.070 |
Why?
|
Female | 12 | 2021 | 392544 | 0.070 |
Why?
|
Medical Oncology | 2 | 2022 | 2320 | 0.060 |
Why?
|
Chromosomes, Mammalian | 1 | 2006 | 147 | 0.060 |
Why?
|
Survival Analysis | 2 | 2021 | 10088 | 0.060 |
Why?
|
Educational Status | 1 | 2012 | 2510 | 0.060 |
Why?
|
Adaptation, Psychological | 2 | 2012 | 2632 | 0.060 |
Why?
|
NFATC Transcription Factors | 1 | 2006 | 390 | 0.060 |
Why?
|
Attitude to Health | 1 | 2012 | 2026 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2018 | 64681 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9457 | 0.050 |
Why?
|
Quinuclidines | 1 | 2022 | 25 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 8003 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10218 | 0.050 |
Why?
|
Tennessee | 1 | 2021 | 119 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2004 | 654 | 0.050 |
Why?
|
Gene Dosage | 1 | 2006 | 1217 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5300 | 0.050 |
Why?
|
Muscle, Skeletal | 2 | 2007 | 4947 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12976 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2022 | 344 | 0.040 |
Why?
|
Muscle Proteins | 1 | 2006 | 1149 | 0.040 |
Why?
|
Adult | 9 | 2023 | 221119 | 0.040 |
Why?
|
Censuses | 1 | 2021 | 198 | 0.040 |
Why?
|
Grief | 2 | 2012 | 254 | 0.040 |
Why?
|
Boston | 1 | 2012 | 9327 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 355 | 0.040 |
Why?
|
Signal Transduction | 2 | 2021 | 23416 | 0.040 |
Why?
|
Decision Making | 1 | 2012 | 3931 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 558 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 29687 | 0.040 |
Why?
|
Survival Rate | 1 | 2012 | 12728 | 0.040 |
Why?
|
Risk Factors | 5 | 2021 | 74239 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2021 | 455 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 697 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 850 | 0.040 |
Why?
|
Down Syndrome | 1 | 2006 | 901 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 734 | 0.040 |
Why?
|
Gene Expression | 2 | 2007 | 7571 | 0.030 |
Why?
|
Wound Healing | 1 | 2007 | 2800 | 0.030 |
Why?
|
Point Mutation | 1 | 2021 | 1593 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2871 | 0.030 |
Why?
|
Regeneration | 1 | 2004 | 1505 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2329 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 987 | 0.030 |
Why?
|
Prevalence | 1 | 2012 | 15721 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2023 | 2058 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 4015 | 0.030 |
Why?
|
Warfarin | 1 | 2022 | 1482 | 0.030 |
Why?
|
Reference Values | 1 | 2021 | 4921 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2023 | 11067 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13632 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3134 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20588 | 0.030 |
Why?
|
Young Adult | 2 | 2018 | 59221 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2021 | 2024 | 0.030 |
Why?
|
Mental Disorders | 1 | 2012 | 6823 | 0.020 |
Why?
|
Fluorouracil | 1 | 2017 | 1642 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2021 | 2803 | 0.020 |
Why?
|
Hemorrhage | 1 | 2022 | 3422 | 0.020 |
Why?
|
Risk Assessment | 2 | 2022 | 24021 | 0.020 |
Why?
|
Family Therapy | 1 | 2011 | 214 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9416 | 0.020 |
Why?
|
Inpatients | 1 | 2021 | 2545 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1662 | 0.020 |
Why?
|
Mice | 5 | 2021 | 81326 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41496 | 0.020 |
Why?
|
Hospices | 1 | 2011 | 245 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7033 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2022 | 4574 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11856 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2021 | 80674 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3744 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5493 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6486 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7571 | 0.020 |
Why?
|
Anticoagulants | 1 | 2022 | 4795 | 0.020 |
Why?
|
Genomics | 1 | 2022 | 5828 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14675 | 0.020 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2006 | 227 | 0.020 |
Why?
|
Computer Systems | 1 | 2007 | 470 | 0.020 |
Why?
|
Myogenin | 1 | 2004 | 54 | 0.020 |
Why?
|
Glucose | 1 | 2017 | 4342 | 0.020 |
Why?
|
Pyrimidines | 1 | 2017 | 3027 | 0.010 |
Why?
|
Wounds, Penetrating | 1 | 2007 | 314 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5333 | 0.010 |
Why?
|
Neural Cell Adhesion Molecules | 1 | 2004 | 122 | 0.010 |
Why?
|
MyoD Protein | 1 | 2004 | 141 | 0.010 |
Why?
|
Macrophage-1 Antigen | 1 | 2004 | 286 | 0.010 |
Why?
|
Freezing | 1 | 2004 | 311 | 0.010 |
Why?
|
Animals | 5 | 2021 | 168079 | 0.010 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2007 | 543 | 0.010 |
Why?
|
Receptors, CCR2 | 1 | 2004 | 214 | 0.010 |
Why?
|
Time Factors | 2 | 2021 | 39957 | 0.010 |
Why?
|
Muscle Strength | 1 | 2007 | 624 | 0.010 |
Why?
|
Transgenes | 1 | 2006 | 1008 | 0.010 |
Why?
|
Muscle Contraction | 1 | 2007 | 1200 | 0.010 |
Why?
|
Coloring Agents | 1 | 2004 | 561 | 0.010 |
Why?
|
Myositis | 1 | 2004 | 270 | 0.010 |
Why?
|
Calcium-Binding Proteins | 1 | 2006 | 1067 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10707 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2017 | 3609 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8663 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2004 | 2468 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16952 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4567 | 0.010 |
Why?
|
Neovascularization, Physiologic | 1 | 2007 | 1347 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2007 | 1720 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2007 | 3777 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2007 | 22127 | 0.010 |
Why?
|
Fibrosis | 1 | 2004 | 2051 | 0.010 |
Why?
|
Mental Health | 1 | 2012 | 3251 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2426 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2012 | 4487 | 0.010 |
Why?
|
Models, Genetic | 1 | 2006 | 3430 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 6067 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 2007 | 2493 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15841 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2006 | 9520 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2004 | 3313 | 0.010 |
Why?
|
United States | 1 | 2020 | 72339 | 0.010 |
Why?
|
Depression | 1 | 2011 | 8132 | 0.010 |
Why?
|
Apoptosis | 1 | 2007 | 9477 | 0.010 |
Why?
|
Macrophages | 1 | 2004 | 5753 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2004 | 12747 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2004 | 14392 | 0.010 |
Why?
|
Phenotype | 1 | 2006 | 16575 | 0.000 |
Why?
|
Inflammation | 1 | 2007 | 10759 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2006 | 18220 | 0.000 |
Why?
|